PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
43.31%
Revenue growth above 1.5x CSIQ's 14.76%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
28.15%
Gross profit growth at 50-75% of CSIQ's 46.34%. Martin Whitman would question if cost structure or brand is lagging.
-38.47%
Negative EBIT growth while CSIQ is at 218.25%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
573.02%
Operating income growth above 1.5x CSIQ's 134.90%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
423.62%
Net income growth at 75-90% of CSIQ's 531.35%. Bill Ackman would press for improvements to catch or surpass competitor performance.
423.08%
EPS growth at 75-90% of CSIQ's 487.50%. Bill Ackman would push for improved profitability or share repurchases to catch up.
423.08%
Diluted EPS growth at 50-75% of CSIQ's 571.43%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
0.29%
Share count expansion well above CSIQ's 0.07%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.55%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
57.45%
OCF growth of 57.45% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
73.33%
FCF growth of 73.33% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
628.87%
5Y revenue/share CAGR under 50% of CSIQ's 5137.54%. Michael Burry would suspect a significant competitive gap or product weakness.
90.49%
3Y revenue/share CAGR at 50-75% of CSIQ's 146.42%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
-150.34%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-68.28%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
457.79%
Below 50% of CSIQ's 1258.99%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
93.42%
Below 50% of CSIQ's 2377.67%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
371.33%
Equity/share CAGR of 371.33% while CSIQ is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
37.60%
Below 50% of CSIQ's 175.77%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.97%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
7.14%
Inventory growth well above CSIQ's 7.68%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-15.11%
Negative asset growth while CSIQ invests at 4.87%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.77%
We have a declining book value while CSIQ shows 5.54%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-41.06%
We’re deleveraging while CSIQ stands at 1.17%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
19.42%
We increase R&D while CSIQ cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-2.90%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.